171 related articles for article (PubMed ID: 38255799)
21. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
22. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.
Sheu MJ; Li CF; Lin CY; Lee SW; Lin LC; Chen TJ; Ma LJ
Tumour Biol; 2014 Aug; 35(8):7755-63. PubMed ID: 24810927
[TBL] [Abstract][Full Text] [Related]
24. ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Yoon G; Park JY; Kim HJ; Choi GS; Kim JG; Kang BW; Kang MK; Seo AN
Anticancer Res; 2019 Jun; 39(6):2845-2853. PubMed ID: 31177122
[TBL] [Abstract][Full Text] [Related]
25. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
26. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
[TBL] [Abstract][Full Text] [Related]
27. Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients.
Jessberger J; Erlenbach-Wünsch K; Posselt R; Haderlein M; Agaimy A; Fietkau R; Hartmann A; Distel L
J Dig Dis; 2017 May; 18(5):283-291. PubMed ID: 28342240
[TBL] [Abstract][Full Text] [Related]
28. High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.
Redalen KR; Sitter B; Bathen TF; Grøholt KK; Hole KH; Dueland S; Flatmark K; Ree AH; Seierstad T
Radiother Oncol; 2016 Feb; 118(2):393-8. PubMed ID: 26705680
[TBL] [Abstract][Full Text] [Related]
29. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
[TBL] [Abstract][Full Text] [Related]
30. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.
Sim SH; Kang MH; Kim YJ; Lee KW; Kim DW; Kang SB; Eom KY; Kim JS; Lee HS; Kim JH
BMC Cancer; 2014 Apr; 14():241. PubMed ID: 24708484
[TBL] [Abstract][Full Text] [Related]
31. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors in locally advanced rectal cancer treated with preoperative hyperfractionated and accelerated radiotherapy.
Bouzourene H; Bosman FT; Matter M; Coucke P
Hum Pathol; 2003 Jun; 34(6):541-8. PubMed ID: 12827607
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
34. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
35. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer.
Tweedle EM; Khattak I; Ang CW; Nedjadi T; Jenkins R; Park BK; Kalirai H; Dodson A; Azadeh B; Terlizzo M; Grabsch H; Mueller W; Myint S; Clark P; Wong H; Greenhalf W; Neoptolemos JP; Rooney PS; Costello E
Gut; 2010 Nov; 59(11):1501-10. PubMed ID: 20947885
[TBL] [Abstract][Full Text] [Related]
36. Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.
Suzuki T; Sadahiro S; Tanaka A; Okada K; Saito G; Kamijo A; Akiba T; Kawada S
Int J Clin Oncol; 2015 Dec; 20(6):1130-9. PubMed ID: 25833701
[TBL] [Abstract][Full Text] [Related]
37. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Cienfuegos JA; Rotellar F; Baixauli J; Beorlegui C; Sola JJ; Arbea L; Pastor C; Arredondo J; Hernández-Lizoáin JL
Ann Surg Oncol; 2015 Mar; 22(3):916-23. PubMed ID: 25190129
[TBL] [Abstract][Full Text] [Related]
38. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
39. The prognostic role of apoptosis mediators in rectal adenocarcinoma.
Seicean R; Crisan D; Boers JE; Mocan T; Seicean A; Funariu G; Ciuce C
Hepatogastroenterology; 2011; 58(110-111):1490-4. PubMed ID: 21940317
[TBL] [Abstract][Full Text] [Related]
40. Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis.
Yao YF; Du CZ; Chen N; Chen P; Gu J
Dis Colon Rectum; 2014 May; 57(5):602-7. PubMed ID: 24819100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
